Prior Authorization Criteria



AKYNZEO (netupitant/palonosetron) PA Criteria:

INDICATIONS AND USAGE:

Akynzeo capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

Akynzeo capsules are a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. Akynzeo for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Akynzeo for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Diagnosis:	ICD-10 code(s) plus description:
Initial authorizat	ion: 6 months:
(Answers to ALL the following should be YES):	
□Yes □No	Age 18 years or older;
AND	
 □Yes □No 	Documented diagnosis of cancer OR antineoplastic history
AND	
vomiting as	is being prescribed for the prevention of acute and delayed nausea and ssociated with initial and repeat courses of cancer chemotherapy, but not limited to, highly emetogenic chemotherapy
AND • □Yes □No	History of prior use of preferred combination antiemetic therapy
• □Yes □No	Concurrent use of dexamethasone per Package Insert labeling
Highly emetogen	ic chemotherapy*
• Day 1: Akyr <i>OR</i>	nzeo 1 (one) capsule 1 (one) hour prior to initiation of chemotherapy
Akyı chemotherapy	nzeo 1 vial infused over 30 minutes starting 30 minutes before
AND	
Dexa chemothera	amethasone: Twelve (12) mg – administer 30 minutes prior to

Updated: 2/3/2020 V2 Page 1

Effective: 7/16/2018

• Day 2 and 4: Dexamethasone eight (8) mg once a day

Anthracyclines and Cyclophosphamide-Based Chemotherapy and Chemotherapy Not Considered Highly Emetogenic

- Day 1: Akynzeo One (1) capsule one (1) hour prior to initiation of chemotherapy *AND*
 - Dexamethasone: Twelve (12) mg administer 30 minutes prior to initiation of chemotherapy.

How Supplied:

Akynzeo (300 mg netupitant/0.5 mg palonosetron) capsules

- One capsule in one blister or pack of four capsules (two capsules per blister strip) **Akynzeo (235 mg fosnetupitant/0.25 mg palonosetron) for injection:**
 - Sterile, white to off-white lyophilized powder in single-dose vial for reconstitution)pack of one vial

Reauthorization: 6 months

* Class of emetogenic therapy as defined by FDA label, compendia or NCCN guidelines

Limitations of Use

• Akynzeo for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy

Quantity Limits: 1 capsule per chemotherapy session.

Updated: 2/3/2020 V2 Page 2

Effective: 7/16/2018